0.2867
12.39%
+0.0316
After Hours:
.2797
-0.007
-2.44%
Jaguar Health Inc stock is currently priced at $0.2867, with a 24-hour trading volume of 30.09M.
It has seen a +12.39% increased in the last 24 hours and a +60.80% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $0.261 pivot point. If it approaches the $0.289 resistance level, significant changes may occur.
Previous Close:
$0.2551
Open:
$0.2642
24h Volume:
30.09M
Market Cap:
$82.35M
Revenue:
$10.72M
Net Income/Loss:
$-39.71M
P/E Ratio:
-0.0184
EPS:
-15.5542
Net Cash Flow:
$-32.21M
1W Performance:
-7.37%
1M Performance:
+60.80%
6M Performance:
-21.45%
1Y Performance:
-57.19%
Jaguar Health Inc Stock (JAGX) Company Profile
Name
Jaguar Health Inc
Sector
Industry
Phone
415 371 8300
Address
200 Pine Street, Suite 400, San Francisco, CA
Jaguar Health Inc Stock (JAGX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-07-21 | Initiated | Cantor Fitzgerald | Overweight |
Jul-11-17 | Initiated | Rodman & Renshaw | Buy |
Jaguar Health Inc Stock (JAGX) Latest News
Jaguar Health (NASDAQ:JAGX) Stock Price Passes Above 50-Day Moving Average of $0.15 - MarketBeat
MarketBeat
Jaguar Health, Inc. (NASDAQ:JAGX) Q1 2024 Earnings Call Transcript - Insider Monkey
Insider Monkey
Jaguar Health (NASDAQ:JAGX) Share Price Passes Above 50-Day Moving Average of $0.15 - Defense World
Defense World
Jaguar Health (NASDAQ:JAGX) Receives New Coverage from Analysts at StockNews.com - MarketBeat
MarketBeat
StockNews.com Begins Coverage on Jaguar Health (NASDAQ:JAGX) - Defense World
Defense World
Earnings call: Jaguar Health reports Q1 2024 revenue increase - Investing.com
Investing.com
Jaguar Health Inc Stock (JAGX) Financials Data
Jaguar Health Inc (JAGX) Revenue 2024
JAGX reported a revenue (TTM) of $10.72 million for the quarter ending September 30, 2023, a -0.51% decline year-over-year.
Jaguar Health Inc (JAGX) Net Income 2024
JAGX net income (TTM) was -$39.71 million for the quarter ending September 30, 2023, a +26.71% increase year-over-year.
Jaguar Health Inc (JAGX) Cash Flow 2024
JAGX recorded a free cash flow (TTM) of -$32.21 million for the quarter ending September 30, 2023, a +12.74% increase year-over-year.
Jaguar Health Inc (JAGX) Earnings per Share 2024
JAGX earnings per share (TTM) was -$6.9342 for the quarter ending September 30, 2023, a +88.98% growth year-over-year.
About Jaguar Health Inc
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea; orphan-drug indications for symptomatic relief of diarrhea in infants and children with congenital diarrheal disorders and for adult and pediatric patients for short bowel syndrome with intestinal failure with; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops lechlemer, a second-generation anti-secretory agent for cholera; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.
Cap:
|
Volume (24h):